337 related articles for article (PubMed ID: 14685005)
21. Pimagedine: a novel therapy for diabetic nephropathy.
Abdel-Rahman E; Bolton WK
Expert Opin Investig Drugs; 2002 Apr; 11(4):565-74. PubMed ID: 11922864
[TBL] [Abstract][Full Text] [Related]
22. Effects of combined lipoic acid and pyridoxine on albuminuria, advanced glycation end-products, and blood pressure in diabetic nephropathy.
Noori N; Tabibi H; Hosseinpanah F; Hedayati M; Nafar M
Int J Vitam Nutr Res; 2013; 83(2):77-85. PubMed ID: 24491880
[TBL] [Abstract][Full Text] [Related]
23. Oral supplementation of turmeric attenuates proteinuria, transforming growth factor-β and interleukin-8 levels in patients with overt type 2 diabetic nephropathy: a randomized, double-blind and placebo-controlled study.
Khajehdehi P; Pakfetrat M; Javidnia K; Azad F; Malekmakan L; Nasab MH; Dehghanzadeh G
Scand J Urol Nephrol; 2011 Nov; 45(5):365-70. PubMed ID: 21627399
[TBL] [Abstract][Full Text] [Related]
24. Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial.
Joergensen C; Tarnow L; Goetze JP; Rossing P
Diabet Med; 2015 Mar; 32(3):374-81. PubMed ID: 25307511
[TBL] [Abstract][Full Text] [Related]
25. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
26. Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA): a randomized double-blind placebo-controlled trial of high- vs. low-dose atorvastatin(1).
Rutter MK; Prais HR; Charlton-Menys V; Gittins M; Roberts C; Davies RR; Moorhouse A; Jinadev P; France M; Wiles PG; Gibson JM; Dean J; Kalra PA; Cruickshank JK; Durrington PN
Diabet Med; 2011 Jan; 28(1):100-8. PubMed ID: 21166851
[TBL] [Abstract][Full Text] [Related]
27. Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease.
Williams ME
Curr Diab Rep; 2004 Dec; 4(6):441-6. PubMed ID: 15539009
[TBL] [Abstract][Full Text] [Related]
28. Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.
Schjoedt KJ; Astrup AS; Persson F; Frandsen E; Boomsma F; Rossing K; Tarnow L; Rossing P; Parving HH
Diabetologia; 2009 Jan; 52(1):46-9. PubMed ID: 18974967
[TBL] [Abstract][Full Text] [Related]
29. A controlled clinical trial of angiotensin-converting enzyme inhibition in type I diabetic nephropathy: study design and patient characteristics. The Collaborative Study Group.
Bain R; Rohde R; Hunsicker LG; McGill J; Kobrin S; Lewis EJ
J Am Soc Nephrol; 1992 Oct; 3(4 Suppl):S97-103. PubMed ID: 1457767
[TBL] [Abstract][Full Text] [Related]
30. Effect of deferiprone, an oral iron chelator, in diabetic and non-diabetic glomerular disease.
Rajapurkar MM; Hegde U; Bhattacharya A; Alam MG; Shah SV
Toxicol Mech Methods; 2013 Jan; 23(1):5-10. PubMed ID: 22978744
[TBL] [Abstract][Full Text] [Related]
31. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Katayama S; Yamada D; Nakayama M; Yamada T; Myoishi M; Kato M; Nowack C; Kolkhof P; Yamasaki Y;
J Diabetes Complications; 2017 Apr; 31(4):758-765. PubMed ID: 28025025
[TBL] [Abstract][Full Text] [Related]
32. Hypoxia in the diabetic kidney is independent of advanced glycation end-products.
Nordquist L; Liss P; Fasching A; Hansell P; Palm F
Adv Exp Med Biol; 2013; 765():185-193. PubMed ID: 22879032
[TBL] [Abstract][Full Text] [Related]
33. The effect of ruboxistaurin on nephropathy in type 2 diabetes.
Tuttle KR; Bakris GL; Toto RD; McGill JB; Hu K; Anderson PW
Diabetes Care; 2005 Nov; 28(11):2686-90. PubMed ID: 16249540
[TBL] [Abstract][Full Text] [Related]
34. Lipid modulation in insulin-dependent diabetes mellitus: effect on microvascular outcomes.
Fried LF; Forrest KY; Ellis D; Chang Y; Silvers N; Orchard TJ
J Diabetes Complications; 2001; 15(3):113-9. PubMed ID: 11358679
[TBL] [Abstract][Full Text] [Related]
35. Prevention and reversal of diabetic nephropathy in db/db mice treated with alagebrium (ALT-711).
Peppa M; Brem H; Cai W; Zhang JG; Basgen J; Li Z; Vlassara H; Uribarri J
Am J Nephrol; 2006; 26(5):430-6. PubMed ID: 16974073
[TBL] [Abstract][Full Text] [Related]
36. Current therapeutic interventions in the glycation pathway: evidence from clinical studies.
Engelen L; Stehouwer CD; Schalkwijk CG
Diabetes Obes Metab; 2013 Aug; 15(8):677-89. PubMed ID: 23279611
[TBL] [Abstract][Full Text] [Related]
37. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study.
Parving HH; Tarnow L; Nielsen FS; Rossing P; Mandrup-Poulsen T; Osterby R; Nerup J
Diabetes Care; 1999 Mar; 22(3):478-83. PubMed ID: 10097932
[TBL] [Abstract][Full Text] [Related]
38. Effect of protein kinase Cbeta inhibition on renal hemodynamic function and urinary biomarkers in humans with type 1 diabetes: a pilot study.
Cherney DZ; Konvalinka A; Zinman B; Diamandis EP; Soosaipillai A; Reich H; Lorraine J; Lai V; Scholey JW; Miller JA
Diabetes Care; 2009 Jan; 32(1):91-3. PubMed ID: 18945921
[TBL] [Abstract][Full Text] [Related]
39. A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations.
Reutens AT; Jandeleit-Dahm K; Thomas M; Salim A; De Livera AM; Bach LA; Colman PG; Davis TME; Ekinci EI; Fulcher G; Hamblin PS; Kotowicz MA; MacIsaac RJ; Morbey C; Simmons D; Soldatos G; Wittert G; Wu T; Cooper ME; Shaw JE
Contemp Clin Trials; 2020 Mar; 90():105892. PubMed ID: 31740428
[TBL] [Abstract][Full Text] [Related]
40. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.
Elving LD; Wetzels JF; van Lier HJ; de Nobel E; Berden JH
Diabetologia; 1994 Jun; 37(6):604-9. PubMed ID: 7926346
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
